Precigen lays off staff, pauses multiple CAR-T programs and all preclinical work and aims for $30M offering
Maryland biotech Precigen said it will lay off more than 20% of its workforce, pause multiple CAR-T clinical programs, halt all …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
